Skip to content

Biological Biomarkers in MOMS Partnership

Biological Biomarkers in MOMS Partnership

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02438514
Enrollment
20
Registered
2015-05-08
Start date
2014-11-30
Completion date
2019-11-30
Last updated
2020-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychological Stress

Brief summary

The investigators propose to evaluate the potential utility of stress-related biomarkers obtained via dried blood spots (DBS) and retinal scans by collecting new data from mothers and children within the New Haven MOMS Partnership, a well-established community-partnered research setting. The proposed research could greatly advance the application of stress-related biomarkers within community-based research by increasing our understanding of how stress, trauma, and depression influence biology in childhood and adulthood, as measured using minimally-invasive approaches.

Interventions

OTHERBiological Sample Collection

Anthropomorphic biomarkers including height, weight, heart rate, and blood pressure will be taken for each participating mother and child by a research assistant trained to accurately perform these procedures. Blood spots will be collected in finger stick proficiency, using trigger activated lancets to administer finger sticks. Each participating mothers and child will provide a saliva sample using Oragene DNA saliva collection kits

Sponsors

Yale University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* English-speaking adult mothers (age 21 or older) of at least one biological child mothers must be able to answer three verification questions to confirm they are the biological parent of their child

Exclusion criteria

* Non-english speakers * Women not able to provide informed consent and with no biological children * Mothers under the age of 21

Design outcomes

Primary

MeasureTime frameDescription
Number of Mother-Child Dyads Who Complete Assessments & Biological SamplesEnd of study (approximately 5 years)Feasibility outcome
Telomere LengthAt baseline-After 90 minutesTelomere length will be measured using an adapted method of the Cawthon Telomere Assay
Advanced Glycation End Products (AGEs)At baseline-After 90 minutesAGEs or (advanced glycation endproducts) will be measured using a painless non- invasive retinal scanning device that measures autofluorescence of the crystalline lens of the eye

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026